Previous 10 | Next 10 |
Gainers: Creative Medical Technology (NASDAQ:CELZ) +33%. HOOKIPA Pharma (NASDAQ:HOOK) +18%. Zynex ZYXI +17%. AMN Healthcare Services (NYSE:AMN) +15%. ShockWave Medical (NASDAQ:SWAV) +10%. Losers: Baudax Bio (NASDAQ:BXRX) -11%. Nuvectis Pharma (NASDAQ:NVCT)...
Gainers: HOOKIPA Pharma (NASDAQ:HOOK) +55%. Upstart Holdings (NASDAQ:UPST) +32%. Eqonex (NASDAQ:EQOS) +19%. Singularity (NASDAQ:SGLY) +15%. Alkermes (NASDAQ:ALKS) +14%. Generac Holdings (NYSE:GNRC) +14%. MYT Netherlands (NYSE:MYTE) +12%. MRC Global (NYSE:MRC) +12%. NextDecade (NASDAQ:NEXT) +1...
Gainers: HOOKIPA Pharma (NASDAQ:HOOK) +46%. Kinnate Biopharma (NASDAQ:KNTE) +9%. Corcept Therapeutics (NASDAQ:CORT) +7%. Alkermes (NASDAQ:ALKS) +5%. Celularity (NASDAQ:CELU) +3%. Losers: Masimo (NASDAQ:MASI) -36%. Baudax Bio (NASDAQ:BXRX) -20%. ...
Buying Penny Stocks Today? Here’s What You Need to Know Buying penny stocks involves understanding what is going on in the market daily. Because penny stocks are so speculative, they tend to react heavily to any and all news that comes out. So, to make money with small-caps, ...
HOOKIPA (NASDAQ:HOOK) shares are 51% higher in after-hours trading after it amended an agreement with Gilead Sciences (NASDAQ:GILD) for the development of an arenaviral immunotherapy as part of a HIV regimen. In 2018, Gilead (GILD) licensed exclusive right to HOOKIPA's arenaviral pl...
HOOKIPA to develop arenaviral-based therapeutic for HIV through Phase 1b clinical trial completion; Gilead has exclusive rights for further program development thereafter Financial terms include $15 million initiation fee and $35 million equity commitment NEW YORK and VIEN...
NEW YORK and VIENNA, Austria, Feb. 09, 2022 (GLOBE NEWSWIRE) -- HOOKIPA Pharma Inc. (NASDAQ: HOOK, ‘HOOKIPA’), a company developing a new class of immunotherapeutics based on its proprietary arenavirus platform, today announced that the company will participate in the virtual ...
First patient dosed with HB-200 and pembrolizumab combination for treatment of 1 st -line advanced/metastatic head and neck cancer in Phase 2 arm of ongoing Phase 1/2 trial Fast Track Designation granted for HB-200 in combination with pembrolizumab for treatment of 1 st -l...
NEW YORK and VIENNA, Austria, Jan. 04, 2022 (GLOBE NEWSWIRE) -- HOOKIPA Pharma Inc. (NASDAQ: HOOK, ‘HOOKIPA’), a company developing a new class of immunotherapeutics based on its proprietary arenavirus platform, today announced that the Company will present at the virtual H.C....
NEW YORK and VIENNA, Austria, Dec. 03, 2021 (GLOBE NEWSWIRE) -- HOOKIPA Pharma Inc. (NASDAQ: HOOK, ‘HOOKIPA’), a company developing a new class of immunotherapeutics based on its proprietary arenavirus platform, today announced that HOOKIPA’s management team will partic...
News, Short Squeeze, Breakout and More Instantly...
Director Dr. Malte Peters named Chief Executive Officer and Director Terry Coelho named Executive Vice President and Chief Financial Officer Company is conducting a review of its business operations and strategy to determine best path to create shareholder value and realize the full potential...
A look at the top 10 most actives in the United States Longeveron Inc. (LGVN) rose 69.0% to $4.8499 on volume of 46,980,986 shares Virpax Pharmaceuticals Inc. (VRPX) rose 161.5% to $3.0333 on volume of 46,199,502 shares Maxeon Solar Technologies Ltd. (MAXN) fell 0.6% to $0.2464 on volume ...
2024-07-09 09:02:05 ET Hookipa Pharma Inc (HOOK) announced stock split at a ratio of 1-for-10 on 2024-07-10 ... Full story available on KlickAnalytics.com